Article

Faster visual recovery next goal for refractive surgery

Although patients undergoing thin-flap LASIK performed with modern femtosecond and excimer lasers can expect excellent vision on the day after surgery, faster visual recovery might enhance the procedure’s appeal, according to Daniel S. Durrie, MD.

 

Kansas City, KS-Although patients undergoing thin-flap LASIK performed with modern femtosecond and excimer lasers can expect excellent vision on the day after surgery, faster visual recovery might enhance the procedure’s appeal, according to Daniel S. Durrie, MD.

“Patients considering refractive surgery want to know how quickly they will be able to get back to work,” said Dr. Durrie, professor of clinical ophthalmology and director of refractive surgery, University of Kansas Medical Center, Kansas City. “I think we could really grow our refractive practices if the surgery developed to the point where patients became immediately functional, and therefore did not have to bring a driver with them to their procedure.”

With that goal in mind, Dr. Durrie has been evaluating a possible role for an investigational silicone ocular shield (NexisVision). The device is rigid in the center and soft at the edges, and by trapping fluid beneath it, the shield supplements the optics of the healing cornea and therefore may improve vision.

 

Continue to page 2

 

Investigation of the potential benefit of the shield is a work in process, he said, but preliminary data show it significantly improved the speed of visual recovery in patients undergoing sub-Bowman’s keratomileusis.

In order to gauge visual recovery, Dr. Durrie has been conducting prospective studies in which patients treated with different excimer and femtosecond lasers have uncorrected visual acuity (UCVA; binocular and monocular) and mesopic contrast sensitivity measured immediately postoperatively, and then at 30 minutes, 1 hour, 2 hours, 4 hours, 1 day, and 1 month after surgery.

Patients are also asked at those time points if they are able to read a text message on their phone and if they would feel comfortable driving.

In a series of patients who had the shield placed after surgery, UCVA was 20/30 or better in 95% of patients immediately after surgery, and in 100% by 1 hour. In contrast, in a cohort of patients without the shield, only 40% saw 20/30 or better immediately postoperatively, and only 71% had 20/30 or better UCVA at 1 hour.

 

Continue to page 3

 

Patients with the shield also had significantly better mesopic contrast sensitivity early after surgery, and subjectively, they felt their visual function was better as well. Nevertheless, even with the shield, the majority of patients still did not feel comfortable driving at 30 minutes or 1 hour after their procedure.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.